Progenics shares rise on positive opinion
-
- April
- 24
Shares of Progenics Pharmaceuticals Inc. surged $2.61, or 32.5 percent, today as the Eastview-based biotechnology company announced that regulators in Europe offered a positive opinion of a product candidate that would treat constipation in certain patients. Progenics and Wyeth Pharmaceuticals are seeking to develop and market the drug, called Relistor. The Committee for Medicinal Products for Human Use will send is opinion to the European Commission, the company said. Progenics shares closed at $10.64. Shares of Wyeth, which has a campus in Pearl River, rose 12 cents to close at $44.56.
This entry was posted
on Thursday, April 24th, 2008 at 4:03 pm by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
